ASH 2022 – Shirley D’Sa
Shirley D’Sa discusses the results of the first clinical trial investigating checkpoint inhibition in relapsed/refractory Waldenström’s macroglobulinemia as well as other immunotherapeutic agents or combinations that might be worth investigating in this setting and explains the association of type I cryoglobulinemia with WM, IgM monoclonal gammopathy of undetermined significance or non-Hodgkin Lymphoma.
Here is the full ASH 2022 report.
More posts
Potential strategies to overcome relapsed and refractory Waldenström’s macroglobulinemia
Potential strategies to overcome relapsed and refractory Waldenström’s macroglobulinemia
Preface – ASH 2022
Preface – ASH 2022 © Lebens.Med Zentrum Bad Erlach - Stefan Vogt, MD, Lebens.Med Zent